search
Back to results

General Decolonization With Octenisan® Set Before Elective Orthopedic Surgery (BALGDEC)

Primary Purpose

Elective Surgery, High Risk, Prevention of Surgical Site Infections

Status
Recruiting
Phase
Phase 3
Locations
Switzerland
Study Type
Interventional
Intervention
Whole Body and nasal decolonization with octenidin (Octenisan Set)
Questionnaire for study participants immediately after the decolonization
Sponsored by
Balgrist University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Elective Surgery focused on measuring Body and nasal decolonization, Adult orthopedic surgery, Prevention of Surgical Site Infections, Randomized-controlled trial

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Age ≥ 18 years Patients with an age ≥ 80 years (as considered particularly at risk for SSI) Elective orthopedic surgery at the Balgrist Chronic immune-suppression (diabetes mellitus, active cancer, cirrhosis CHILD C, renal dialysis, untreated HIV disease, medicamentous immune-suppression equivalent to prednisone ≥ 10 mg/day) Elective surgery in ischemic skin (e.g. major amputations) Elective surgery on non-diabetic and non-infected ulcerated skin Tumor (oncologic) orthopedic surgery ASA-Scores 3-4 points Exclusion Criteria: Elective revision orthopedic surgery due to orthopedic infection within the last 12 months in the same area of surgery Emergency surgery (defined as planned surgery within the next 48 hours) Surgery on infected skin; or surgery under antibiotic treatment for any reason "Diabetic foot surgery" (distinct clinical entity; defined as below the ankle) Body mass index ≥ 35 kg/m2 (anticipated difficulty of effective decolonization) Pregnancy (formality reasons) Intolerance or allergy to octenidin and/or ingredients in the Octenisan® set Use of any other topical antiseptic agents other than Octenisan® set (except for the duration of one day) Patient unable to understand; or under legal guardian for medical decisions Anticipated clinical follow-up of less than 6 weeks after surgery. ASA-Scores 1-2, and ASA-Score 5 (high risk of postoperative complications) Known skin colonization with antibiotic-multiresistant Gram-negative organisms defined by infection control protocols of Switzerland1

Sites / Locations

  • Balgrist University Hospital
  • Balgrist University HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Decolonization

Non-Decolonization

Arm Description

This study will be performed with an existing "set" manufactured by Schülke & Mayr GmbH. The distribution of octenisan® wash lotion and octenisan® nasal gel in the form of a set (octenisan® set) largely streamlines and facilitates the application and compliance. The duration of pre-surgical decolonization is planned to be five days. However, when this pre-surgical time period is too short, the decolonization may also start at least 3 days before surgery and be contin-ued up to 2 days post-surgery. During the post-surgery application, the patient will be washed with water and Octenisan® set by their treating nurses. The patient will also return the empty/used set and answer to a short questionnaire during their hospital stay. The study team will recuperate the questionnaire during hospitalization.

No Decolonization preoperatively

Outcomes

Primary Outcome Measures

Remission (and inversely surgical site infection)
Remission is defined as the absence of clinical, anamnestic, radiologic or laboratory signs of infection.
Wound problems after elective surgery
Wound problems (dehiscence, seroma, hematoma, necrosis) occurring after surgery

Secondary Outcome Measures

Unplanned revision surgery for non-infection problems in same time period
Any revision in the operating theatre due to non-infectious pathologies
Adverse events
All adverse events during the decolonization and hospitalization periods
Subjective opinion and information on the decolonization
Questionnaire with 5 questions only for patients being decolonized

Full Information

First Posted
November 30, 2022
Last Updated
August 14, 2023
Sponsor
Balgrist University Hospital
Collaborators
Industry (Schülke & Mayr AG, Switzerland and Germany)
search

1. Study Identification

Unique Protocol Identification Number
NCT05647252
Brief Title
General Decolonization With Octenisan® Set Before Elective Orthopedic Surgery
Acronym
BALGDEC
Official Title
General Skin and Nasal Decolonization With Octenisan® Set Be-fore and After Elective Orthopedic Surgery in Selected Patients at Elevated Risk for Revision Surgery and Surgical Site Infections
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
February 27, 2023 (Actual)
Primary Completion Date
January 31, 2025 (Anticipated)
Study Completion Date
April 30, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Balgrist University Hospital
Collaborators
Industry (Schülke & Mayr AG, Switzerland and Germany)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The general decolonization of the human body surface by industrial antiseptic agents, before elective surgery is recommended by the World Health Organization (WHO). A specific randomized-controlled trial specifically among high-risk adult orthopedic patients for infection has not been performed. In this single-center, prospective, randomized, and controlled superiority trial, which is planned over a period of two years, we target on an orthopedic patient population with an elevated risk for revision surgery and surgical site infections
Detailed Description
The general decolonization of the human body surface and, of adjacent pathogen reservoirs such as the nose, by industrial antiseptic agents by the World Health Organization (WHO) for the risk reduction of superficial and deep surgical site infection (SSI). Such a decolonization is regarded as evidence-based in the majority of randomized, and before-after trials, since two decades, although negative studies also exist. In the orthopedic field, this decolonization is likely to be more effective in elective patients with a proven body colonization of Staphylococcus aureus. The decolonization might be equally efeective in orthopedic patients with an inherent high risk for SSI, for which the majority of future SSI pathogens are skin commensals and S. aureus. These (eventual and future) pathogens of SSI are accessible to the topical agents during the index surgery, if the patients are well instructed and know how to decolonize themselves. In contrast, this pre-surgical decolonization is only a supplementary measure in the bundle of all combined efforts to prevent revision surgery for infection. Its individual power is limited for young, healthy individuals, for SSIs caused by pathogens from the internal body sites (intestinal, urinary, gynecologic regions), infections acquired on the surgical ward, and in settings with less specialized surgeries and a low volume of surgical experience. Hence, in trials including all patients (or only those carrying S. aureus), the beneficial effect of decolonization can be diluted and provoke an additional costly and cumber-some organizational procedure for the majority of patients with low to moderate SSI risks. Moreover, many surgical site infections in orthopedic surgery, especially in implant-related surgery, are more due to coagulase-negative staphylococci (CoNS) than for S. aureus. The hallmark of the CoNS group is S. epidermidis with approximatively 70% resistance (in Switzerland) to standard prophylactic antibiotic agents9, As S. epidermidis is part of the normal human flora, typically the skin flora, and, only becomes pathogenic under certain conditions, a screening for this microorganism is not feasible in common practice,. while the prophylaxis-resistant part of all orthopedic SSI pathogens is at 30-50%. In this single-center, prospective, randomized, and controlled superiority trial, which is planned over a period of two years, we target on an orthopedic patient population with an elevated risk for revision sur-gery and SSI; inde-pendently of a known body carriage for S. aureus. This study will be performed with an existing "set" manufactured by Schülke & Mayr GmbH. The "Set" was placed on the market in 2016. The distribution of Octenisan® wash lotion and Octenisan® nasal gel in the form of a set (Octenisan® Set) largely streamlines and facilitates the organizational application and compliance efforts of the study. Academically and clinically, we will gain insight in the performance of decolonization for a patient population at particular risk of postoperative complications, where every effort to prevent infection is of importance.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Elective Surgery, High Risk, Prevention of Surgical Site Infections, Randomized-controlled Trial
Keywords
Body and nasal decolonization, Adult orthopedic surgery, Prevention of Surgical Site Infections, Randomized-controlled trial

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
Single-Center, Unblinded, Superiority, Randomized-Controlled Trial (Randomization 1:1)
Masking
None (Open Label)
Allocation
Randomized
Enrollment
1000 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Decolonization
Arm Type
Experimental
Arm Description
This study will be performed with an existing "set" manufactured by Schülke & Mayr GmbH. The distribution of octenisan® wash lotion and octenisan® nasal gel in the form of a set (octenisan® set) largely streamlines and facilitates the application and compliance. The duration of pre-surgical decolonization is planned to be five days. However, when this pre-surgical time period is too short, the decolonization may also start at least 3 days before surgery and be contin-ued up to 2 days post-surgery. During the post-surgery application, the patient will be washed with water and Octenisan® set by their treating nurses. The patient will also return the empty/used set and answer to a short questionnaire during their hospital stay. The study team will recuperate the questionnaire during hospitalization.
Arm Title
Non-Decolonization
Arm Type
No Intervention
Arm Description
No Decolonization preoperatively
Intervention Type
Drug
Intervention Name(s)
Whole Body and nasal decolonization with octenidin (Octenisan Set)
Intervention Description
Octenidin body lotion once a day during the five consecutive days preceding the elective orthopedic surgery, including for the hair. Octenidin nasal creme 2-3 times a day in both nasal orifices during the same period
Intervention Type
Behavioral
Intervention Name(s)
Questionnaire for study participants immediately after the decolonization
Intervention Description
A questionnaire in GErman language will be handed out to decolonized patients with five questions: Practical difficulties of decolonization, the completeness of scheduled decolonization actions, all adverse events during decolonization and surgery, and two questions regarding the comprehension of the science (indication for decolonization, potential benefit expected in the individual case). The questionnaire is handmade and validated by the Investigators.
Primary Outcome Measure Information:
Title
Remission (and inversely surgical site infection)
Description
Remission is defined as the absence of clinical, anamnestic, radiologic or laboratory signs of infection.
Time Frame
At 6 weeks after elective orthopedic surgery; or at 1 year for surgeries with orthopedic implants
Title
Wound problems after elective surgery
Description
Wound problems (dehiscence, seroma, hematoma, necrosis) occurring after surgery
Time Frame
Until week 6 after surgery
Secondary Outcome Measure Information:
Title
Unplanned revision surgery for non-infection problems in same time period
Description
Any revision in the operating theatre due to non-infectious pathologies
Time Frame
At 6 weeks after elective orthopedic surgery; or at 1 year for surgeries with orthopedic implants
Title
Adverse events
Description
All adverse events during the decolonization and hospitalization periods
Time Frame
At 6 weeks after elective orthopedic surgery; or at 1 year for surgeries with orthopedic implants
Title
Subjective opinion and information on the decolonization
Description
Questionnaire with 5 questions only for patients being decolonized
Time Frame
A day within one week after surgery (during the hospitalization)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥ 18 years Patients with an age ≥ 80 years (as considered particularly at risk for SSI) Elective orthopedic surgery at the Balgrist Chronic immune-suppression (diabetes mellitus, active cancer, cirrhosis CHILD C, renal dialysis, untreated HIV disease, medicamentous immune-suppression equivalent to prednisone ≥ 10 mg/day) Elective surgery in ischemic skin (e.g. major amputations) Elective surgery on non-diabetic and non-infected ulcerated skin Tumor (oncologic) orthopedic surgery ASA-Scores 3-4 points Exclusion Criteria: Elective revision orthopedic surgery due to orthopedic infection within the last 12 months in the same area of surgery Emergency surgery (defined as planned surgery within the next 48 hours) Surgery on infected skin; or surgery under antibiotic treatment for any reason "Diabetic foot surgery" (distinct clinical entity; defined as below the ankle) Body mass index ≥ 35 kg/m2 (anticipated difficulty of effective decolonization) Pregnancy (formality reasons) Intolerance or allergy to octenidin and/or ingredients in the Octenisan® set Use of any other topical antiseptic agents other than Octenisan® set (except for the duration of one day) Patient unable to understand; or under legal guardian for medical decisions Anticipated clinical follow-up of less than 6 weeks after surgery. ASA-Scores 1-2, and ASA-Score 5 (high risk of postoperative complications) Known skin colonization with antibiotic-multiresistant Gram-negative organisms defined by infection control protocols of Switzerland1
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ilker Uçkay, Prof.
Phone
+41443863705
Email
ilker.uckay@balgrist.ch
First Name & Middle Initial & Last Name or Official Title & Degree
Thorsten Studhalter, RN
Phone
+41443863707
Email
thorsten.studhalter@balgrist.ch
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ilker Uçkay, Prof.
Organizational Affiliation
Balgrist University Hospital, Zürich, Switzerland
Official's Role
Principal Investigator
Facility Information:
Facility Name
Balgrist University Hospital
City
Zürich
State/Province
Zurich
ZIP/Postal Code
8008
Country
Switzerland
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ilker Uckay, Prof.
Phone
+41 44 386 37 05
Email
ilker.uckay@balgrist.ch
First Name & Middle Initial & Last Name & Degree
Thorsten Studhalter, RN
Phone
+41443863707
Email
thorsten.studhalter@balgrist.ch
First Name & Middle Initial & Last Name & Degree
Ines Unterfrauner, MD
Facility Name
Balgrist University Hospital
City
Zürich
Country
Switzerland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ilker Uçkay
Phone
+41443863705
Email
Ilker.uckay@balgrist.ch

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
The Study Protocol will be published separately The results of the study will be a publication
IPD Sharing Time Frame
Before and after the study (February 2023 and May 2025)
IPD Sharing Access Criteria
Will be published in PubMed
Citations:
PubMed Identifier
23414705
Citation
Uckay I, Hoffmeyer P, Lew D, Pittet D. Prevention of surgical site infections in orthopaedic surgery and bone trauma: state-of-the-art update. J Hosp Infect. 2013 May;84(1):5-12. doi: 10.1016/j.jhin.2012.12.014. Epub 2013 Feb 14.
Results Reference
result
PubMed Identifier
29671723
Citation
Tsang STJ, McHugh MP, Guerendiain D, Gwynne P, Boyd J, Laurenson IF, Templeton KE, Lewis S, Simpson AHRW, Walsh TS. Evaluation of Staphylococcus aureus eradication therapy in orthopaedic surgery. J Med Microbiol. 2018 Jun;67(6):893-901. doi: 10.1099/jmm.0.000731. Epub 2018 Apr 19.
Results Reference
result
PubMed Identifier
27601492
Citation
Dancer SJ, Christison F, Eslami A, Gregori A, Miller R, Perisamy K, Robertson C, Graves N. Is it worth screening elective orthopaedic patients for carriage of Staphylococcus aureus? A part-retrospective case-control study in a Scottish hospital. BMJ Open. 2016 Sep 6;6(9):e011642. doi: 10.1136/bmjopen-2016-011642.
Results Reference
result
PubMed Identifier
36084332
Citation
Prentice HA, Chan PH, Champsi JH, Clutter DS, Maletis GB, Mohan V, Namba RS, Reddy NC, Hinman AD, Fang AS, Yian E, Navarro RA, Norheim EP, Paxton EW. Temporal Trends in Deep Surgical Site Infections After Six Orthopaedic Procedures Over a 12-year Period Within a US-based Healthcare System. J Am Acad Orthop Surg. 2022 Nov 1;30(21):e1391-e1401. doi: 10.5435/JAAOS-D-22-00280. Epub 2022 Sep 7.
Results Reference
result
PubMed Identifier
32058435
Citation
Rohrer F, Notzli H, Risch L, Bodmer T, Cottagnoud P, Hermann T, Limacher A, Fankhauser N, Wagner K, Brugger J. Does Preoperative Decolonization Reduce Surgical Site Infections in Elective Orthopaedic Surgery? A Prospective Randomized Controlled Trial. Clin Orthop Relat Res. 2020 Aug;478(8):1790-1800. doi: 10.1097/CORR.0000000000001152.
Results Reference
result
Links:
URL
https://www.schuelke.com/wMedia/docs/folder-broschueren/infektionspraevention/schuelke_Praevention-schlaegt-Infektion_Folder-2021.pdf
Description
Octenidin Set (Manufacturer's information)

Learn more about this trial

General Decolonization With Octenisan® Set Before Elective Orthopedic Surgery

We'll reach out to this number within 24 hrs